Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Siwy, J; Schanstra, JP; Argiles, A; Bakker, SJ; Beige, J; Boucek, P; Brand, K; Delles, C; Duranton, F; Fernandez-Fernandez, B; Jankowski, ML; Al Khatib, M; Kunt, T; Lajer, M; Lichtinghagen, R; Lindhardt, M; Maahs, DM; Mischak, H; Mullen, W; Navis, G; Noutsou, M; Ortiz, A; Persson, F; Petrie, JR; Roob, JM; Rossing, P; Ruggenenti, P; Rychlik, I; Serra, AL; Snell-Bergeon, J; Spasovski, G; Stojceva-Taneva, O; Trillini, M; von der Leyen, H; Winklhofer-Roob, BM; Zürbig, P; Jankowski, J.
Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.
Nephrol Dial Transplant. 2014; 29(8):1563-1570
Doi: 10.1093/ndt/gfu039
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Roob Johannes
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Diabetic nephropathy (DN) is one of the major late complications of diabetes. Treatment aimed at slowing down the progression of DN is available but methods for early and definitive detection of DN progression are currently lacking. The 'Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria trial' (PRIORITY) aims to evaluate the early detection of DN in patients with type 2 diabetes (T2D) using a urinary proteome-based classifier (CKD273). In this ancillary study of the recently initiated PRIORITY trial we aimed to validate for the first time the CKD273 classifier in a multicentre (9 different institutions providing samples from 165 T2D patients) prospective setting. In addition we also investigated the influence of sample containers, age and gender on the CKD273 classifier. We observed a high consistency of the CKD273 classification scores across the different centres with areas under the curves ranging from 0.95 to 1.00. The classifier was independent of age (range tested 16-89 years) and gender. Furthermore, the use of different urine storage containers did not affect the classification scores. Analysis of the distribution of the individual peptides of the classifier over the nine different centres showed that fragments of blood-derived and extracellular matrix proteins were the most consistently found. We provide for the first time validation of this urinary proteome-based classifier in a multicentre prospective setting and show the suitability of the CKD273 classifier to be used in the PRIORITY trial. © The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Diabetes Mellitus, Type 2 - complications
- Diabetes Mellitus, Type 2 - diagnosis
- Diabetes Mellitus, Type 2 - urine
- Diabetic Nephropathies - diagnosis
- Diabetic Nephropathies - etiology
- Diabetic Nephropathies - urine
- Diagnosis, Differential -
- Disease Progression -
- Female -
- Follow-Up Studies -
- Humans -
- Male -
- Middle Aged -
- Peptidomimetics - urine
- Prospective Studies -
- Proteomics - methods
- Find related publications in this database (Keywords)
- biomarkers
- chronic kidney disease
- diabetic nephropathy
- diagnosis
- urine proteomics